INBS vs IDXX

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). IDEXX Laboratories, Inc. (IDXX) offers the better valuation at 43. 7x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -99. 8% for Intelligent Bio Solutions Inc. (INBS). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus INBS's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IDEXX Laboratories, Inc.

(IDXX) is the lower-risk stock at 1. 36β versus Intelligent Bio Solutions Inc. 's 1. 85β — meaning INBS is approximately 36% more volatile than IDXX relative to the S&P 500. On balance sheet safety, Intelligent Bio Solutions Inc. (INBS) carries a lower debt/equity ratio of 10% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). On earnings-per-share growth, the picture is similar: Intelligent Bio Solutions Inc. grew EPS 68. 7% year-over-year, compared to 22. 6% for IDEXX Laboratories, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -346. 2% for Intelligent Bio Solutions Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -348. 7% for INBS. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+542. 3% 10Y return). Intelligent Bio Solutions Inc. (INBS) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDXX: +542. 3%, INBS: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.